Informal norms in global governance: Human rights, intellectual property rules and access to medicines

Informal Norms in Global Governance: Human Rights, Intellectual Property Rules and Access to Medicines

Volumn , Issue , 2013, Pages 1-241

  Hein, Wolfgang ^a   Moon, Suerie ^b  

^a GIGA GERMAN INSTITUTE OF GLOBAL AND AREA STUDIES   (Germany)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899355249     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (437)

1. Abbott, F. M. (2005). The WTO Medicines Decision: World Pharmaceutical Trade and the Protection of Public Health. The American Journal of International Law, 99(2), 317-358.
2. Abbott, F. M. (2006). TRIPS II, Asia and the Mercantile Pharmaceutical War: Implications for Innovation and Access (Draft paper for the Conference on Economic Challenges in Asia, Stanford Center for International Development). Retrieved from http://www.stanford.edu/group/siepr/cgi-bin/siepr/?q=system/files/shared/pubs/papers/pdf/SCID308.pdf.
3. Abbott, F. M. (2009). Seizure of Generic Pharmaceuticals in Transit Based on Allegations of Patent Infringement: A Threat to International Trade, Development and Public Welfare. World Intellectual Property Organization Journal (WIPO), Vol. 1, p. 43, 2009. Retrieved from http://ssrn.com/paper=1535521.
4. Abbott, F. M., Correa, C. M. and Biadgleng, E. T. (2007). World Trade Organization Accession Agreements: Intellectual Property Issues (Global Economic Issues Publication. Geneva: Quaker United Nations Office). Retrieved from http://www.quno.org/geneva/pdf/economic/Issues/WTO-IP-English.pdf.
5. Adelman, C. C. and Norris, J. (2004). Myths and Realities on Prices of Drugs. Washington, DC: The Hudson Institute. Retrieved from http://www.hudson.org/files/publications/AdelmanARVWhitePaper.pdf.
6. Adler, E. and Haas, P. M. (1992). Conclusion: Epistemic Communities, World Order, and the Creation of a Reflective Research Program. International Organization, 46(01), 367. doi:10.1017/S0020818300001533.
7. Agence France Press (AFP). (2009, 28 October). Firms Accept Ecuador Plan to Break Pharma Patents. Retrieved from http://www.google.com/hostednews/afp/article/ALeqM5gQ3gR0DaSBmVlSg-luegX4ziFtDQ.
8. Allen, T., Levin, S., Waxman, H., et al. (2007). Letter to Susan Schwab. Retrieved from http://www.cptech.org/ip/health/c/thailand/congressional-schwabletter-thailand-10jan06.pdf.
9. Alter, K. J. and Meunier, S. (2009). The Politics of International Regime Complexity. Perspectives on Politics, 7(1), 13. doi:10.1017/S1537592709090033. Retrieved from http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=3998488&fulltextType=BT&fileId=S1537592709090033RD.
10. Amendment of the TRIPS Agreement - Second Extension of the Period for the Acceptance by Members of the Protocol Amending the TRIPS Agreement. WT/L/785 U.S.C. (2009).
11. American University Program on Information Justice and Intellectual Property. (2011). Trans-Pacific Partnership Agreement. Retrieved from http://www.wcl.american.edu/pijip/go/tpp.
12. Anderson, B. (1983). Imagined Communities: Reflections on the Origin and Spread of Nationalism. London: Verso.
13. Anheier, H., Glasius, M. and Kaldor, M. (eds) (2004). Global Civil Society Yearbook 2004/05. Oxford: Oxford University Press.
14. Appelbaum, R. P., Felstiner, W. L. and Gessner, V. (eds) (2001). Rules and Networks: The Legal Culture of Global Business Transactions. Oxford: Hart Publishing.
15. Arts, B., Noortmann, M. and Reinalda, B. (eds) (2001). Non-State Actors in International Relations. Aldershot: Ashgate.
16. AstraZeneca. (2010). AstraZeneca Corporate Responsibility-Dedicated TB Research. Retrieved from http://www.astrazeneca.com/about-us/?itemId=7537532.
17. Baker, D. (2004). Financing Drug Research: What are the Issues? (Submission to the WHO Commission on Intellectual Property, Innovation and Public Health. Issue Brief). Washington, DC: Center for Economic and Policy Research. Retrieved from http://www.who.int/intellectualproperty/news/en/Submission-Baker.pdf.
18. Baker, G. and Chandler, D. (eds) (2005). Global Civil Society: Contested Futures. London: Routledge.
19. Bale, H. (1999). IFPMA Position on Compulsory Licensing Treatment Access Forum Listserve. Retrieved from http://lists.essential.org/pharm-policy/msg00060.html.
20. Banerjee, A., Hollis, A. and Pogge, T. (2010). The Health Impact Fund: Incentives for Improving Access to Medicines. The Lancet, 375(9709), 166-169. doi:10.1016/S0140-6736(09)61296-4.
21. Barbosa-Filho, N. H. (2008). Inflation Targeting in Brazil: 1999-2006. International Review of Applied Economics, 22(2), 187. Retrieved from http://www.informaworld.com/10.1080/02692170701880684.
22. Barnett, M. and Duvall, R. (2005). Power in Global Governance. In M. Barnett and R. Duvall (eds), Power in Global Governance (pp. 1-32). New York: Cambridge University Press.
23. Bartlett, C., Kickbusch, I. and Coulombier, D. (2006). Cultural and Governance Influence on Detection, Identification and Monitoring of Human Disease. (Infectious Diseases: Preparing for the Future) Foresight Project. Retrieved from http://www.foresight.gov.uk/Infectious%20Diseases/d4_3.pdf.
24. Bartsch, S. and Kohlmorgen, L. (2007a). The Role of Civil Society Organizations in Global Health Governance. In W. Hein, S. Bartsch and L. Kohlmorgen (eds), Global Health Governance and the Fight Against HIV/AIDS (pp. 92-118). Basingstoke: Palgrave Macmillan.
25. Bartsch, S. and Kohlmorgen, L. (2007b). The Role of Southern Actors in Global Governance (GIGA Working Paper No. 46). Hamburg: German Institute of Global and Area Studies.
26. Bartsch, S., Huckel Schneider, C. and Kohlmorgen, L. (2009). Governance Norms in Global Health: Key Concepts. In K. Buse, W. Hein and N. Drager (eds), Making Sense of Global Governance: A Policy Perspective (pp. 99-121). Basingstoke: Palgrave Macmillan.
27. Beck, U. and Lau, C. (2004). Entgrenzung und Entscheidung. Frankfurt: Suhrkamp.
28. Bell, C., Devarajan, S. and Gersbach, H. (2004). Thinking about the Long-Run Economic Costs of AIDS. In M. Haacker (ed.), The Macroeconomics of HIV/AIDS (pp. 96-133). Washington, DC: International Monetary Fund.
29. Berkman, A., Garcia, J., Munoz-Laboy, M., et al. (2005). A Critical Analysis of the Brazilian Response to HIV/AIDS: Lessons Learned for Controlling and Mitigating the Epidemic in Developing Countries. American Journal of Public Health, 95(7), 1162-1172. doi:10.2105/AJPH.2004.054593.
30. Bermann, G. A. and Mavroidis, P. C. (eds) (2006). Trade and Human Health and Safety. New York: Cambridge University Press.
31. Bermudez, J. and 'tHoen, E. (2010). The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good. The Open AIDS Journal, 4, 37-40. doi:10.2174/1874613601004020037. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842943/?tool=pmcentrez.
32. Berndt, E. R., Glennerster, R., Kremer, M. R., et al. (2007). Advance Market Commitments for Vaccines against Neglected Diseases: Estimating Costs and Effectiveness. Health Economics, 16(5), 491-511. doi:10.1002/hec.1176.
33. Berridge, V., Loughlin, K. and Herring R. (2009). Historical Dimensions of Global Health Governance. In K. Buse, W. Hein and N. Drager (eds), Making Sense of Global Health Governance: A Policy Perspective (pp. 28-46). Basingstoke: Palgrave Macmillan.
34. Betz, J. (2002). Maßnahmen Gegen Kinderarbeit: Nützliches Und Weniger Nützliches. Peripherie. Zeitschrift für Politik und Ökonomie in der Dritten Welt, 22(85/86), 144-161.
35. Bhatiasevi, A. and Maneerungsee, W. (February 2, 2000). HIV/AIDS-Compulsory ddI Licensing Seen Unlikely. The Bangkok Post.
36. Bliss, K. (2010). Key Players in Global Health. How Brazil, Russia, India, China, and South Africa are Influencing the Game. Washington, DC: Center for Strategic and International Studies.
37. Blouin, C., Chopra, M. and van der Hoeven, R. (2009). Trade and Social Determinants of Health. The Lancet, 373(9662), 502-507. doi:10.1016/S0140 -6736(08)61777-8.
38. Blouin, C., Drager, N. and Smith, R. (eds) (2006). International Trade in Health Services and the GATS: Current Issues and Debates. Washington, DC: The World Bank.
39. Bodansky, D. and Crook, J. R. (2002). Symposium: The ILC's State Responsibility Articles. The American Journal of International Law, 96, 773-791. http://www.asil.org/ajil/ilcsymp1.pdf.
40. Böhringer, C. and Frondel, M. (2002). Assessing Voluntary Commitments: Monitoring is Not Enough (Discussion Paper 02-62). Mannheim: Zentrum für Europäische Wirtschaftsforschung.
41. Boyd, B., Henning, N., Reyna, E., et al. (2009). Hybrid Organizations. New Business Models for Environmental Leadership. Sheffield: Greenleaf.
42. Bradsher, K. (October 12, 2005). Roche Faces Pressure over Birdflu Medicine. The New York Times. Retrieved from http://www.nytimes.com/2005/10/11/health/11iht-tamiflu.html.
43. Braithwaite, J. and Drahos, P. (2000). Global Business Regulation. New York: Cambridge University Press.
44. Braudel, F. (1958). Histoire et Sciences sociales. La longue duree. Annales. Économies, Sociétés, Civilisations, 13, 4, 725-753.
45. Brown, T. M., Cueto, M. and Fee, E. (2006). The World Health Organization and the Transition from "International" to "Global" Public Health. American Journal of Public Health, 96(1), 62-72. doi:10.2105/AJPH.2004.050831, http://www.ajph.org/cgi/content/abstract/96/1/62.
46. Buckley, S. (September 17, 2000). Brazil Becomes Model in Fight Against AIDS; Government, Activists Team to Defy Epidemic through Distribution of Drugs. The Washington Post, pp. A22.
47. Burris, S. (2004). Governance, Microgovernance and Health, in Temple Law Review, 77, 343-362. Retrieved from http://www.ilazarte.com.ar/epss/mt-static/archives/documentos/Microgovernance_Burris.pdf.
48. Burris, S. C., Drahos, P. and Shearing, C. D. (2005). Nodal Governance. Australian Journal of Legal Philosophy, 30.
49. Burris, S., Kempa, M. and Shearing, C. (2008). Changes in Governance: A Cross- Disciplinary Review of Current Scholarship. Akron Law Review, 41(1), 1-66.
50. Busby, J. (2006). From Benign Neglect to Moral Awakening: Donor Responses to HIV/AIDS Centre for Globalisation and Governance, Princeton University.
51. Buse, K. and Walt, G. (2002). Globalisation and Multilateral Public-Private Health Partnerships: Issues for Health Policy. In K. Lee, K. Buse and S. Fustukian (eds), Health Policy in a Globalising World (pp. 41-62). Cambridge: Cambridge University Press.
52. Calcagnotto, G. (2007). Consensus-Building on Brazilian HIV/AIDS Policy: National and Global Interfaces in Health Governance. In Hein, W., Bartsch, S. and Kohlmorgen, L. (eds), Global Health Governance and the Fight Against HIV/AIDS (pp. 172-201).
53. Cancer Patients Aid Association (CPAA), Lawyers Collective HIV/AIDS Unit, Delhi Network for Positive People (DNP+) and Médecins Sans Frontières (August 7, 2000). Joint Statement by CPAA, MSF, DNP+ and Lawyers Collective on Novartis Judgment. Retrieved from http://keionline.org/content/view/120/1.
54. Cardoso, F. H. (1999). In Serra J., Lopes Tápias A. (eds), Presidential Decree on Compulsory Licensing: Decree 3.201 of October 6, 1999 [Decreto no.3.201 de 06 de Outubro de 1999]. Brasilia. Retrieved from http://www.cptech.org/ip/health/c/brazil/PresDecree.html.
55. Cawthorne, P., Ford, N., Limpananont, J., et al. (2007). WHO must Defend Patients' Interests, Not Industry. The Lancet, 369(9566), 974-975. doi:10.1016/S0140-6736(07)60473-5,
56. Cernuschi, T. (2009). Pneumococcal AMC. Tropical Medicine and International Health, 14, 103-104.
57. Champ, P. and Attaran, A. (2002). Patent Rights and Local Working Under the WTO TRIPS Agreement: An Analysis of the U.S.-Brazil Patent Dispute. The Yale Journal of International Law, 27, 365.
58. Chan, M. (February 7, 2007). Letter to Dr. Mongkol Na Songkhla. Retrieved from http://lists.essential.org/pipermail/ip-health/2007-February/010538.html.
59. Chaudhuri, S. (2010). The Indian Pharmaceutical Industry after TRIPS. In Chaudhuri, S., Park, C. and Gopakumar, K.M. (eds), Five Years into the Product Patent Regime: India's Response (pp. 19-72). New York: UNDP.
60. Chee, Y. L. (2006). Malaysia: 'Government use' Route to Importing Generic Medicines. Third World Resurgence, 196.
61. Chen, L. C., Evans, T. G. and Cash, R. A. (1999). Health as a Global Public Good. In I. Kaul, I. Grunberg and M. A. Stern (eds), Global Public Goods: International Cooperation in the 21st Century (pp. 284-304). Oxford and New York: Oxford University Press.
62. Chequer, P., Cuchí, P., Mazin, R. and García Calleja, J. M. (2000). Access to Antiretroviral Treatment in Latin American Countries and the Caribbean. AIDS, 16(Supplement 3), S50-S57.
63. Chien, C. V. (2007). HIV/AIDS Drugs for Sub-Saharan Africa: How do Brand and Generic Supply Compare? PLoS ONE, 2(3), e278. doi:10.1371/journal. pone.0000278, http://dx.doi.org/10.1371/journal.pone.0000278.
64. Chow, J. (2010). Is the WHO Becoming Irrelevant? Foreign Policy, December 8. Retrieved from http://www.foreignpolicy.com/articles/2010/12/08/is_the_who_becoming_irrelevant.
65. Clapham, A., Robinson, M., Mahon, C. and Jerbi, S. (2009). Realizing the Right to Health. Swiss Human Rights Book (Vol. 3, ed.). Zurich: rüffer&rub.
66. Clapham, A. (2006). Human Rights Obligations of Non-State Actors. Oxford: Oxford University Press.
67. Clinton, W. J. (1999). Remarks at a World Trade Organization Luncheon in Seattle (December 1, 1999). Weekly Compilation of Presidential Documents, 35, 2494-2497.
68. Clinton, W. J. (2000). Executive Order no 13155.
69. Coleman, M. P., Quaresma, M., Berrino, F., et al (2008). Cancer survival in five continents: A worldwide population-based study (CONCORD) [Abstract]. The Lancet Oncology, 9(8) 730-756.
70. Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). (2006). Public Health, Innovation and Intellectual Property Rights. Geneva: World Health Organization (WHO). Retrieved from http://www.who.int/intellectualproperty/report/en/index.html.
71. Commission on Macroeconomics and Health. (2001). Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization. Retrieved from http://whqlibdoc.who.int/publications/2001/924154550x.pdf.
72. Commission on Social Determinants of Health. (2008). Closing the Gap in a Generation: Health Equity through Action on the Social Determinants of Health. (Final Report of the Commission on Social Determinants of Health). Geneva: World Health Organization. Retrieved from http://whqlibdoc.who.int/publications/2008/9789241563703_eng.pdf.
73. Committee on Economic, Social and Cultural Rights. (2000). General Comment no. 14: The Right to the Highest Attainable Standard of Health (E/C.12/2000/4, ed.). United Nations Economic and Social Council. Retrieved from http://www.unhchr.ch/tbs/doc.nsf/%28Symbol%29/40d009901358b0e2c1256915005090be?Opendocument.
74. Consumer Project on Technology. (2007). Thailand: Compulsory Licensing Dispute. Retrieved from http://www.cptech.org/ip/health/c/thailand/.
75. Coomans, F. (2005). Progressive Development of International Human Rights Law: Extraterritorial Application of the International Covenant on Economic, Social and Cultural Rights. In M. Windfuhr (ed.), Beyond the Nation State: Human Rights in Times of Globalization (pp. 33-50). Uppsala: Global Publications Foundation.
76. Cooper, H., Zimmerman, R. and McGinley, L. (2001, 2 March). Patents Pending: AIDS Epidemic Traps Drug Firms in a Vise: Treatment Vs. Profits - Suit in South Africa Seeks to Block Generic Copies; U.S. Reverses its Policy - Activists Warn Mr. Papovich. The Wall Street Journal, pp. A1.
77. Cooper, W. H. (2010). Free Trade Agreements: Impact on US Trade and Implications for US Trade Policy, No. RL31356 (Updated February 23, 2010). Washington, DC: Congressional Research Service. Retrieved from http://assets.opencrs.com/rpts/RL31356_20100223.pdf.
78. Correa, C. M. (2002a). Implications of the Doha Declaration on the TRIPS Agreement and Public Health (Health Economics and Drugs EDM Series No. 12). Geneva: World Health Organization. Retrieved from http://apps.who.int/medicinedocs/en/d/Js2301e/.
79. Correa, C. M. (2002b). Protection of Data Submitted for the Registration of Pharmaceuticals: Implementing the Standards of the TRIPS Agreement. Geneva: The South Centre.
80. Correa, C. M. (2004). Bilateral Investment Agreements: Agents of New Global Standards for the Protection of Intellectual Property Rights? GRAIN. Retrieved from http://www.grain.org/briefings/?id=186.
81. Correa, C. M. (2006). Implications of Bilateral Free Trade Agreements on Access to Medicines. Bulletin of the World Health Organization, 84, 399-404.
82. Datta, P. T. J. (April 12, 2010). CSIR Open-Source Project for TB Democratises Research. The Hindu Business Line. Retrieved from http://www.thehindubusinessline.com/2010/04/13/stories/2010041353180200.htm.
83. David, P. A. (1993). Intellectual Property Institutions and the Panda's Thumb: Patents, Copyrights, and Trade Secrets in Economic Theory and History. In Wallerstein, M. B., Mogee, M. E. and Schoen, R. A. (eds), Global Dimensions of Intellectual Property Rights in Science and Technology. The National Academies Press.
84. de Gucht, K. (DG Trade). (May 5, 2010). Letter to Mr. Von Schoen-Angerer on the EU-India FTA European Commission, Directorate-General Trade. Retrieved from http://trade.ec.europa.eu/doclib/docs/2010/may/tradoc_146192.pdf.
85. Dean, M. (1999). Governmentality: Power and Rule in Modern Society. London: Sage.
86. Deere, C. (2008). The Implementation Game: The TRIPS Agreement and the Global Politics of Intellectual Property Reform in Developing Countries. Oxford: Oxford University Press.
87. Denny, C. and Meek, J. (April 19, 2001). Drug Giants made to Swallow Bitter Pill. The Guardian. Retrieved from http://www.guardian.co.uk/world/2001/apr/19/highereducation.aids.
88. DFID. (2005). Increasing People's Access to Essential Medicines in Developing Countries: A Framework for Good Practice in the Pharmaceutical Industry. London: Department for International Development (DFID). Retrieved from http://www.accesstomedicineindex.org/sites/www.accesstomedicineindex.org/files/publication/dfid_2005.pdf.
89. DiMasi, J. A., Hansen, R. W. and Grabowski, H. A. (2003). The Price of Innovation: New Estimates of Drug Development Costs. The Journal of Health Economics, 22, 151-185.
90. DiMasi, J. and Grabowski, H. (2004). Patents and R&D Incentives: Comments on the Hubbard and Love Trade Framework for Financing Pharmaceutical R&D. Paper submitted to the WHO Commission on Intellectual Property, Innovation and Public Health. Retrieved from http://www.who.int/intellectualproperty/news/en/Submission3.pdf.
91. Djelic, M. and Quack, S. (2010). Transnational Communities and Governance. In M. Djelic and S. Quack (eds), Transnational Communities Shaping Global Economic Governance (pp. 3-36). Cambridge: Cambridge University Press.
92. Dodd, R., Schieber, G., Cassels, A., et al (2007). Aid Effectiveness and Health. Working Paper No. 9; WHO/HSS/healthsystems/2007.2. Geneva: World Health Organization.
93. Drahos, P. (2001). Bits and Bips. The Journal of World Intellectual Property, 4(6), 791-808. doi:10.1111/j.1747-1796.2001.tb00138.x, http://dx.doi.org/10.1111/j.1747-1796.2001.tb00138.x.
94. Drahos, P. (2002). Developing Countries and International Intellectual Property Standard-Setting (Study Paper 8). Commission on Intellectual Property Rights. http://www.iprcommission.org/graphic/documents/study_papers.htm.
95. Drahos, P. (2003). Expanding Intellectual Property's Empire: The Role of FTAs. Geneva: GRAIN. Retrieved from http://www.grain.org/rights/TRIPSplus.cfm?id=28.
96. Drahos, P. (2004). Intellectual Property and Pharmaceutical Markets: A Nodal Governance Approach. Temple Law Review, 77, 247-289.
97. Drahos, P. and Braithwaite, J. (2002). Information Feudalism: Who Owns the Knowledge Economy? New York: The New Press.
98. Drezner, D. W. (2006). The Race to the Bottom Hypothesis: An Empirical and Theoretical Review. The Fletcher School, Tufts University (unpublished paper). Retrieved from http://www.danieldrezner.com/archives/003076.html.
99. Drezner, D. W. (2007). All Politics is Global: Explaining International Regulatory Regimes. Princeton, NJ: Princeton University Press.
100. Drezner, D. W. (2009). The Power and Peril of International Regime Complexity. Perspectives on Politics, 7(01), 65. doi:10.1017/S1537592709090100. Retrieved from http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=3998572&fulltextType=BT&fileId=S1537592709090100RD.
101. Dugger, C. W. (May 9, 2007). Clinton Foundation Announces a Bargain on Generic AIDS Drugs. The New York Times, p. 9.
102. Dunning, J. H. (1999). A Business Analytic Approach to Governments and Globalization. In Dunning, J. H. (ed.), Governments, Globalization, and International Business (pp. 114-131). Oxford: Oxford University Press.
103. Durkheim, E. (1982 [1895]). Rules of Sociological Method. New York: Free Press.
104. England, R. (2007). Are we Spending Too Much on HIV? British Medical Journal, 334.
105. Enserink, M. (2006). Oseltamivir becomes Plentiful - but Still Not Cheap. Science, 312(5772), 382-383. doi:10.1126/science.312.5772.382. Retrieved from http://www.sciencemag.org.
106. Epstein, S. (1996). Impure Science: AIDS, Activism, and the Politics of Knowledge. Berkeley: University of California Press.
107. European Commission. (2010). Trade: Creating Opportunities: Bilateral Relations. Retrieved from http://ec.europa.eu/trade/creating-opportunities/bilateral-relations/regions/.
108. European Commission, Directorate General 1. (1998). Note for the Attention of the 113 Committee (Deputies) Subject: WTO TRIPS/World Health Organisation (WHO) - Revised Drug Strategy; Meeting of the "Ad Hoc Working Group" on 13 to 16 October 1998. Brussels: European Commission, Directorate General 1: External relations: Commercial Policy and Relations with North America, the Far East, Australia and New Zealand.
109. European Commission, Directorate Trade. (2009). The Anti-Counterfeiting Agreement (ACTA): Fact Sheet. Retrieved from http://trade.ec.europa.eu/doclib/docs/2009/january/tradoc_142039.pdf.
110. European Commission, Directorate Trade. (2010). EU-India FTA Negotiations and Access to Medicines: Questions and Answers. Brussels: European Commission. Retrieved from http://trade.ec.europa.eu/doclib/docs/2010/may/tradoc_146191.pdf.
111. European Parliament. TRIPS Agreement and Access to Medicines, Resolution P6_TA(2007) 0353. (2007). Retrieved from http://www.europarl.europa.eu/sides/getDoc.do?type=TA&reference=P6-TA-2007-0353&language=EN&ring=B6-2007-0288.
112. Fairclough, N. (1993). Discourse and Social Change. Oxford: Blackwell Publishers.
113. Falk, R. (1995). Liberalism at the Global Level: The Last of the Independent Commissions? Millennium - Journal of International Studies, 24, 563-576.
114. Farmer, P., Frenk, J., Knaul, F. M., et al. (2010). Expansion of cancer care and control in countries of low and middle income: A call to action [Abstract]. The Lancet, 376(9747) 1186-1193.
115. Ferlay, J., Shin, H., Bray, F., et al. (2010). Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127(12), 2893-2917.
116. Fidler, D. (2007). Architecture Amidst Anarchy: Global Health's Quest for Governance. Global Health Governance, 1(1). Retrieved from http://www.ghgj.org/Fidler_Architecture.pdf.
117. Fidler, D. P. (2008a). Influenza Virus Samples, International Law, and Global Health Diplomacy. Emerging Infectious Diseases, 14(1), 88-94. doi:10.3201/eid1401.070700.
118. Fidler, D. P. (2008b). A Theory of Open-Source Anarchy. Indiana Journal of Global Legal Studies, 15(1), Article 11. Retrieved from http://www.repository.law.indiana.edu/ijgls/vol15/iss1/11.
119. Fink, C. and Maskus, K. E. (2005). Intellectual Property and Development: Lessons from Recent Economic Research. Washington, DC: World Bank; New York: Oxford University Press.
120. Fink, S. and Rabinowitz, R. (2011). The UN's Battle with NCDs: How Politics, Commerce, and Science Complicated the Fight Against an "Invisible Epidemic". Foreign Affairs (September), http://www.foreignaffairs.com/print/68197.
121. Finkelstein, S. N. and Temin, P. (2008). Reasonable Rx: Solving the Drug Price Crisis. Upper Saddle River, NJ: FT Press/Pearson Education.
122. Finnemore, M. (1996). Norms, Culture, and World Politics: Insights from Sociology's Institutionalism, International Organization, 50(2), 325-347.
123. Finnemore, M. and Sikkink, K. (1998). International Norm Dynamics and Political Change. International Organization, 52(4), 887-917.
124. Fischer-Lescano, A. and Liste, P. (2005). Völkerrechtspolitik. Zu Trennung und Verknüpfung von Politik und Recht in der Weltgesellschaft. Zeitschrift Für Internationale Beziehungen, 12(2), 209-249. Retrieved from http://www.zib.nomos.de/fileadmin/zib/doc/ZIB_05_02.pdf.
125. Florini, A. and Sovacool, B. K. (2009). Who Governs Energy? The Challenges Facing Global Energy Governance. Energy Policy, 37, 5239-5248.
126. Flynn, S. (2008). Using Competition Law to Promote Access to Medicines. Washington, DC: American University, Washington College of Law: Program on Information Justice and Intellectual Property. Retrieved from http://www.ggp.up.ac.za/human_rights_access_to_medicines/syllabus/2009/day3/3FlynnUsingCompetitionLawtoPromoteAccesstoMedicin.pdf.
127. Flynn, S. M. (2010). Special 301 of the Trade Act of 1974 and Global Access to Medicines. Journal of Generic Medicines, 7, 309-333.
128. Ford, N., Wilson, D., Bunjumnong, O. and von Schoen Angerer, T. (2004). The Role of Civil Society in Protecting Public Health Over Commercial Interests: Lessons from Thailand. The Lancet, 363(9408), 560-563. doi:10.1016/S0140-6736(04)15545-1,
129. Furtado, C. (1970). Economic Development of Latin America. Cambridge: Cambridge University Press.
130. Gaventa, J. and Tandon, R. (2010). Globalizing Citizens: New Dynamics of Inclusion and Exclusion. London: Zed Books.
131. GAVI Alliance Secretariat. (2010). Advance Market Commitment for Pneumococcal Vaccines: Annual Report 12 June 2009-31 March 2010. Geneva.
132. Gehl Sampath, P. (2008). India's Pharmaceutical Sector in 2008: Emerging Strategies and Global and Local Implications for Access to Medicines. London: DFID. Retrieved from www.dfid.gov.uk/Documents/publications/indiapatentreport.pdf.
133. George, J., Sheshadri, R. and Grover, A. (2009). India: Intellectual Property and Access to Medicines: Developments and Civil Society Initiatives in India. In R. Reis, V. Terto Jr. and M. C. Pimenta (eds), Intellectual Property Rights and Access to ARV Medicines: Civil Society Resistance in the Global South (pp. 110-136). Rio de Janeiro: Brazilian Interdisciplinary AIDS Association (ABIA).
134. Gereffi, G. (1983). The Pharmaceutical Industry and Dependency in the Third World. Princeton, NJ: Princeton University Press.
135. Gerhardsen, T. I. S. (February 16, 2007). Drug Company Reacts to Thai License; Government Ready to Talk. Intellectual Property Watch (IP Watch). Retrieved from http://www.ip-watch.org/weblog/2007/02/16/drug-company-upset-by-newest-thai-license-government-open-to-dialogue/.
136. Giridharadas, A. (November 30, 2006). Clinton's Foundation Brokers AIDS Deal. The New York Times. Retrieved from http://www.nytimes.com/2006/11/30/world/asia/01aidscnd.html.
137. Glassman, J. (2004). The Real Obstacle to Treating AIDS, Malaria, and Tuberculosis in Developing Countries. Introductory Remarks. Washington, DC: American Enterprise Institute for Public Policy Research. Retrieved from http://www.aei.org/speech/health/the-real-obstacles-to-treating-aids-malaria-and-tuberculosis-in-developing-countries-speech/.
138. GlaxoSmithKline (2007). GlaxoSmithKline Launches Chinese Research Center with Appointment of Head in Shanghai. Retrieved from http://www.gsk-china.com/asp/News/client/newconten/5242007105329.htm.
139. GlaxoSmithKline (2009a). Big Pharma as a Catalyst for Change. Speech by GSK CEO Andrew Witty at Harvard Medical School, February 13, 2009. Retrieved from http://www.gsk.com/media/Witty-Harvard-Speech-Summary.pdf.
140. GlaxoSmithKline (2009b). GlaxoSmithKline Statement in Response to Paul Hunt's Report on GSK.
141. GlaxoSmithKline (2009b). GlaxoSmithKline Statement in Response to Paul Hunt's Report on GSK.
142. Glyn, A. and Sutcliffe, B. (1972). British Capitalism, Workers and the Profit Squeeze. Harmondswoth: Penguin.
143. Goldstein, J. L., Kahler, M., Keohane, R. O. and Slaughter, A. (eds) (2001). Legalization and World Politics. Cambridge, MA: MIT Press.
144. Governments of Bangladesh, Barbados, Bolivia and Suriname. (2009). Chagas Disease Prize Fund for the Development of New Treatments, Diagnostics and Vaccines. World Health Organization. Retrieved from http://www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_ChagasPrize.pdf.
145. Governments of Bolivia and Suriname. (April 5, 2010). Submission by the Governments of Bolivia and Suriname (on the WHO EWG Report).
146. Grace, C. (2004). Leveraging the Private Sector for Public Health Objectives: A Briefing Paper for DFID on Technology Transfer in the Pharmaceuticals Sector. DFID Health Systems Resource Centre. Retrieved from http://www.dfidhealthrc.org/publications/atm/India%20China%20ATM.pdf.
147. Grace, C. (2005). A Briefing Paper for DFID: Update on China and India and Access to Medicines.
148. Grant, A. D. and De Cock, K. M. (2001). HIV Infection and AIDS in the Developing World. British Medical Journal, 322, 1475-1478.
149. Grover, A. (2009). Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, Anand Grover (A/HRC/11/12). United Nations Human Rights Council.
150. Grover, A. (2011). Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health: Expert Consultation on Access to Medicines as a Fundamental Component of the Right to Health (A/HRC/17/43). Geneva: United Nations Human Rights Council. Retrieved from http://daccess-dds-ny.un.org/doc/UNDOC/GEN/G11/118/42/PDF/G1111842.pdf?OpenElement.
151. Hanim, L. and Jhamtani, H. (2006). Indonesia: Manufacturing Generic AIDS Medicines Under the 'Government use' Approach. Third World Resurgence, 196.
152. Harris, G. (September 18, 2011). China and India Making Inroads on Biotech Drugs. The New York Times. Retrieved from http://www.nytimes.com/2011/09/19/health/policy/19drug.html.
153. Hart, H. L. A. (1961 [1997]). The Concept of Law (2nd ed.). Oxford University Press: Clarendon.
154. Hart, H. L. A. (1973). Essays on Bentham: Jurisprudence and Political Theory. Oxford: Oxford University Press.
155. Health GAP et al. (December 16, 2004). Open Letter to Dr. Manmohan Singh, Prime Minister of India. Retrieved from http://www.healthgap.org/press_releases/04/121604_HGAP_LTR_India_patent.pdf.
156. Health Global Access Project (Health GAP). (2010). Allegation Letter to the United Nations Special Rapporteur on the Right to Health: In the Matter of use of the 'Special 301' Program, Section 182 of the Trade Act of 1974, to Limit Access to Medicines in Violation of the International Right to Health. Retrieved from http://www.healthgap.org/documents/ComplainttoSpecialRapporteur-1.pdf.
157. Hecht, R., Bollinger, L., Stover, J., et al. (2009). Critical Choices in Financing the Response to the Global HIV/AIDS Pandemic. Health Affairs, 28(6), 1591-1605.
158. Hein, W. and Kickbusch, I. (2010). Global Health, Aid Effectiveness and the Changing Role of the WHO (GIGA Focus International Edition, No. 3). Hamburg: German Institute of Global and Area Studies.
159. Hein, W. and Kohlmorgen, L. (2008). Global Health Governance: Conflicts on Global Social Rights. Global Social Policy, 8(1), 80-108.
160. Hein, W., Bartsch, S. and Kohlmorgen, L. (eds) (2007). Global Health Governance and the Fight Against HIV/AIDS. Basingstoke: Palgrave Macmillan.
161. Hein, W., Burris, S. and Shearing, C. (2009). Conceptual Models for Global Health Governance. In K. Buse, W. Hein and N. Drager (eds), Making Sense of Global Health Governance: A Policy Perspective (pp. 72-98). Basingstoke: Palgrave Macmillan.
162. Held, D. (1995). Democracy and the Global Order: From the Modern State to Cosmopolitan Governance. Oxford: Polity Press.
163. Held, D., McGrew, A., Goldblatt, D. and Perraton, J. (1999). Global Transformations: Politics, Economics and Culture. Cambridge: Polity Press.
164. Helfer, L. R. (2004). Regime Shifting: The TRIPs Agreement and New Dynamics of International Intellectual Property Lawmaking. The Yale Journal of International Law, 29, 1.
165. Helfer, L. R. (2009). Regime Shifting in the International Intellectual Property System. Perspectives on Politics, 7(01), 39. doi:10.1017/S1537592709090069. Retrieved from http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=3998524&fulltextType=BT&fileId=S1537592709090069RD.
166. Henkin, L. (1995). International Law. Politics and Values. Doordrecht: Nijhoff Publishers.
167. Hirschler, B. (November 8, 2010). China seen as no. 2 Drugs Market by 2015. Reuters, http://uk.reuters.com/article/2010/11/08/us-summit-china-drugs-idUK TRE6A73SL20101108.
168. Hoekman, B. and Kostecki, M. (2001). The Political Economy of the World Trading System - WTO and Beyond. Oxford: Oxford University Press. doi:http://dx.doi.org/10.1093/019829431X.001.0001.
169. Hogerzeil, H. V., Samson, M., Casanovas, J. V. and Rahmani-Ocora, L. (2006). Is Access to Essential Medicines as Part of the Fulfilment of the Right to Health Enforceable through the Courts? The Lancet, 368(9532), 305-311. doi:10.1016/S0140-6736(06)69076-4.
170. Holmes, C. B., Coggin, W., Jamieson, D., et al. (2010). Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment Programs. Journal of the American Medical Association, 304(3), 313-320. doi:10.1001/jama.2010.993. Retrieved from http://jama.ama-assn.org/cgi/content/full/304/3/313.
171. Holton, R. J. (2005). Making Globalization. Basingstoke: Palgrave.
172. Hookway, J. (June 18, 2010). Philippines Price Controls Hamper Rise of Generics. The Wall Street Journal. Retrieved from http://online.wsj.com/article/SB10001424052748703340904575284061202593520.html.
173. Hubbard, T. and Love, J. (2004a). A New Trade Framework for Global Healthcare R&D. PLoS Biology, 2(2), E52. doi:10.1371/journal.pbio.0020052. Retrieved from http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.0020052.
174. Hubbard, T. and Love, J. (2004b). A New Trade Framework for Global Healthcare R&D. PLoS Biol, 2(2), e52. Retrieved from http://dx.doi.org.ezp-prod1.hul.harvard.edu/10.1371%2Fjournal.pbio.0020052.
175. Huckel Schneider, C. (2009a). Global Public Health and Innovation in Governance: The Emergence of Public-Private Partnerships. In S. J. MacLean, P. Fourie and S. A. Brown (eds), Health for Some (pp. 105-117). Basingstoke: Palgrave.
176. Huckel Schneider, C. (2009b). Legitimacy and Global Governance in Managing Global Public Health. Unpublished PhD, University of Tübingen. Retrieved from http://tobias-lib.uni-tuebingen.de/volltexte/2010/4526/pdf/HuckelSchneiderTobiasLib.pdf.
177. Hunt, P. (2006). Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health (A/61/338). United Nations General Assembly. Retrieved from http://daccess-dds-ny.un.org/doc/UNDOC/GEN/N06/519/97/PDF/N0651997.pdf?OpenElement.
178. Hunt, P. (2009). Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Health, Paul Hunt. Annex: Mission to GlaxoSmithKline (A/HRC/11/12/Add.2). United Nations Human Rights Council.
179. Hutter, B. M. (2006). The Role of Non-State Actors in Regulation. (CARR Discussion Papers, DP 37). London: Centre for Analysis of Risk and Regulation, London School of Economics and Political Science.
180. Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, Decision of the General Council of 30 August 2003 U.S.C. (2003).
181. IMS Health (April 20, 2010). IMS Forecasts Global Pharmaceutical Market Growth of 5-8% Annually through 2014; Maintains Expectations of 4-6% Growth in 2010. FiercePharma.
182. Industria Farmaceutica de Investigacion (IFI) (2009). Boletin Informativo.
183. Inside US Trade (April 15, 2005). Industry Says Indian Drug Law Violates WTO, but no WTO Case seen. Inside US Trade. Retrieved from http://www.cptech.org/ip/health/c/india/insideustrade04152005.html.
184. Intellectual Property Watch (April 21, 2012). Kenya's High Court's Overturning of Anti-Counterfeit Law Hailed. Intellectual Property Watch. Retrieved from http://www.ip-watch.org/2012/04/21/kenyan-high-courts-overturning-of-anticounterfeit-law-hailed/.
185. International Centre for Trade and Sustainable Development (2011). TRIPS Council: Members Debate Biodiversity, Access to Medicine. Bridges Weekly Trade News Digest, 15(8).
186. International Commission on Intervention and State Sovereignty (2001). The Responsibility to Protect. International Development Research Centre.
187. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) (March 22, 2005). Passage of Indian Patent Law: A Step Forward. Retrieved from www.cptech.org/ip/health/c/india/ifpma03222005.html.
188. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) (2007). Partnerships to Build Healthier Societies in the Developing World.
189. International Institute for Sustainable Development (IISD) (2010). Bilateral Investment Treaties and Regional Agreements. Retrieved from http://www.iisd.org/investment/bits/.
190. International Trade Centre (ITC) (2010). Trade Map: Trade Statistics for International Business Development. Retrieved from http://www.trademap.org/Index.aspx.
191. Jenkins, G. W. (2007). Soft Power, Strategic Security, and International Philanthropy. North Carolina Law Review, 85(March), 773-846.
192. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2011). World AIDS Day Report 2011. Geneva: UNAIDS. Retrieved from http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf.
193. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) (2009). 2009 AIDS Epidemic Update (UNAIDS/09.36E/JC1700E). Geneva: UNAIDS/WHO. Retrieved from http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf.
194. Jones, K. (2009). The Doha Blues: Institutional Crisis and Reform at the WTO. Oxford: Oxford University Press.
195. Kanavos, P., Vandoros, S. and Garcia-Gonzalez, P. (2009). Benefits of Global Partnerships to Facilitate Access to Medicines in Developing Countries: A Multi-Country Analysis of Patients and Patient Outcomes in GIPAP. Globalization and Health, 5(1), 19. Retrieved from http://www.globalizationandhealth.com/content/5/1/19.
196. Kaul, I. (2003). Providing Global Public Goods: Managing Globalization. New York: Published for the United Nations Development Programme by Oxford University Press.
197. Kazmin, A. and Jack, A. (November 30, 2006). Thailand Breaks Patent for Aids Drug to Cut Costs. The Financial Times. Retrieved from http://www.ft.com/cms/s/0/5a5fbfd4-8018-11db-a3be-0000779e2340.html?nclick_check=1.
198. Keck, M. E. and Sikkink, K. (1998). Activists Beyond Borders. Ithaca, NY: Cornell University Press.
199. Kell, G. and Ruggie, J. G. (1999). Global Markets and Social Legitimacy: The Case for the "Global Compact". Transnational Corporations, 8(3), 101-120.
200. Kenya Treatment Access Movement (KETAM) and Health Action International Africa (HAI-Africa) (2009). The Anti-Counterfeit Bill, 2008: Concerns on Access to Medicines for Kenyans (Briefing Paper). Retrieved from http://www.haiafrica.org/downloads/anti_counterfeit_bill_factsheet.pdf.
201. Keohane, R. O. and Nye, J. S. (1997). Interdependence in World Politics. In G. T. Crane and A. Amawi (eds), The Theoretical Evolution of International Political Economy: A Reader. New York: Oxford University Press.
202. Khagram, S. (2004). Dams and Development: Transnational Struggles for Water and Power. Ithaca, NY: Cornell University Press.
203. Khagram, S., Riker, J. V. and Sikkink, K. (eds) (2002). Restructuring World Politics: Transnational Social Movements, Networks, and Norms. Minneapolis: University of Minnesota Press.
204. Khor, M. (January 16, 2005). FTA is a 'Matter of Life and Death'. Global Trends. Retrieved from http://www.twnside.org.sg/title2/gtrends87.htm.
205. Khosla, R. and Hunt, P. (2009). Human Rights Guideline for Pharmaceutical Companies in Relation to Access to Medicines: The Sexual and Reproductive Health Context. Colchester: University of Essex Human Rights Centre. http://www.essex.ac.uk/human_rights_centre/research/rth/docs/Final_pharma_for_website.pdf.
206. Kickbusch, I. and Buckett, K. (eds) (2010). Implementing Health in all Policies: Adelaide 2010. Government of South Australia.
207. Kickbusch, I., Hein, W. and Silberschmidt, G. (2010). Addressing Global Health Governance Challenges through a New Mechanism: The Proposal for a Committee C of the World Health Assembly. Journal of Law, Medicine & Ethics, 38, 3, 550-563, retrieved from http://www.ilonakickbusch.com/global-health-governance/committee-c-2010.pdf.
208. Kind, R., Smith, A., Tauscher, E., et al. (March 15, 2007). Letter to Susan C. Schwab. Retrieved from http://www.cptech.org/ip/health/c/thailand/house 03152007.pdf.
209. Kinderman, D. (2010). Free us so we can do some Corporate Responsibility. Ökologisches Wirtschaften, 25, 1, 19-20. Retrieved from http://oekologisches-wirtschaften.de/index.php/oew/article/viewFile/680/680.
210. Kingsbury, K. (November 14, 2007). China's Drug Addiction. Time. Retrieved from http://www.time.com/time/business/article/0,8599,1684180,00.html.
211. Kinney, E. D. and Clark, B. A. (2004). Provisions for Health and Health-Care in the Constitutions of the Countries of the World. Cornell International Law Journal, 37, 285-355. Retrieved from http://indylaw.indiana.edu/instructors/Kinney/Articles/kinney_Constitutions.pdf.
212. Kirchanski, S. (1993). Protection of US Patent Rights in Developing Countries: US Efforts to Enforce Pharmaceutical Patents in Thailand. Loyola Los Angeles International and Comparative Law Journal, 16, 569.
213. Kohlmorgen, L. (2007). International Governmental Organizations and Global Health Governance: The Role of the World Health Organization, World Bank and UNAIDS. In Hein, W., Bartsch, S. and Kohlmorgen, L. (ed.), Global Health Governance and the Fight Against HIV/AIDS (pp. 119-145). Basingstoke: Palgrave Macmillan.
214. Koivusalo, M. (2003). The Impact of WTO Agreements on Health and Development Policies (Policy Brief 3). Helsinki: Globalism and Social Policy Programme. Retrieved from https://gaspp.stakes.fi/NR/rdonlyres/3000F54A-DDCF-48C4-AFFE-056867902724/0/policybrief3.pdf.
215. Kooiman, J. (2003). Governing as Governance. London: Sage.
216. Koppell, J. G. S. (2001). The Politics of Quasi-Government: Hybrid Organizations and the Dynamic of Bureaucratic Control. Cambridge: Cambridge University Press.
217. Koskenniemi, M. (2007). The Fate of Public International Law: Between Technique and Politics. The Modern Law Review, 70(1), 1-30.
218. Krasner, S. D. (1982). Structural Causes and Regime Consequences: Regimes as Intervening Variables. International Organization, 36(2), 185-205.
219. Laing, R., Waning, B., Gray, A., et al. (2003). 25 Years of the WHO Essential Medicines Lists: Progress and Challenges. The Lancet, 361(9370), 1723-1729. doi:10.1016/S0140-6736(03)13375-2.
220. Larkin, B. (1999). US Government Efforts to Negotiate the Repeal, Termination or Withdrawal of Article 15(c) of the South African Medicines and Related Substances Act of 1965. Washington, DC: US Department of State. Retrieved from http://www.cptech.org/ip/health/sa/stdept-feb51999.html.
221. Lee, K. (2009). Understandings of Global Health Governance. The Contested Landscape. In A. Kay and O. D. Williams (eds), Global Health Governance. Crisis, Institutions and Political Economy (pp. 27-41). Basingstoke: Palgrave Macmillan.
222. Leonard, D. K. and Straus, S. (2003). Africa's Stalled Development: International Causes and Cures. Boulder: Lynne Rienner.
223. Licht, A. N. (2008). Social Norms and the Law: Why Peoples Obey the Law. Review of Law & Economics, 4(3), 23-58.
224. Liese, B., Rosenberg, M. and Schratz, A. (2010). Neglected Tropical Diseases: Programmes, Partnerships, and Governance for Elimination and Control of Neglected Tropical Diseases. The Lancet, 375, 67-76.
225. Light, D. W. and Warburton, R. (2011). Demythologizing the High Costs of Pharmaceutical Research. BioSocieties, 6, 34-50. doi:10.1057/biosoc.2010.40; published online February 7, 2011, 1-17.
226. Limpananont, J., Eksaengsri, A., Kijtiwatchakul, K. and Metheny, N. (2009). Thailand: Access to AIDS Treatment and Intellectual Property Rights' Protection in Thailand. In R. Reis, V. Terto Jr. and M. C. Pimenta (eds), Intellectual Property Rights and Access to ARV Medicines: Civil Society Resistance in the Global South (pp. 137-163). Rio de Janeiro: Brazilian Interdisciplinary AIDS Association (ABIA).
227. Linklater, A. (1998). The Transformation of Political Community: Ethical Foundations of the Post-Westphalian Era. Cambridge: Polity Press.
228. Linton, K. C. (2008). China's R&D Policy for the 21st Century: Government Direction of Innovation. SSRN eLibrary. Retrieved from http://ssrn.com/paper=1126651.
229. List, C. and Koenig-Archibugi, M. (2010). Can there be a Global Demos? An Agency-Based Approach. Philosophy & Public Affairs, 38(1), 76-110.
230. Long, N. (1989). Encounters at the Interface. Wageningen: Wageningen Studies in Sociology.
231. Love, J. P. (2007). Recent examples of the use of compulsory licenses on patents (KEI Research Note 2). Washington, DC: Knowledge Ecology International. Retrieved from http://keionline.org/misc-docs/recent_cls_8mar07.pdf.
232. Love, J. (September 16, 2011). Will the UN Backtrack on Accessible Medicine? Al Jazeera. Retrieved from http://www.aljazeera.com/indepth/opinion/2011/09/201191492714279493.html.
233. Love, J. and Hubbard, T. (2009). Prizes for Innovation of New Medicines and Vaccines. Annals of Health Law, 18, 155-186.
234. Macan-Markar, M. (February 2, 2007). WHO Chief's Stand on Generic Drugs Slammed. InterPress Service (IPS). Retrieved from http://ipsnews.net/news.asp?idnews=36420.
235. Mackay, B. (2009). Summary Report of Industry Government Forum on Access to Medicines (IGFAM) (Meeting Report). London: DFID Health Resources Center.
236. MacLeod, D. A. (1992). US Trade Pressure and the Developing Intellectual Property Law of Thailand, Malaysia and Indonesia. University of British Columbia Law Review, 26(343), 346-348.
237. Mandelson, P. (July 10, 2007). Letter to Krirk-Krai Jirapaet. Retrieved from http://www.actupparis.org/IMG/pdf/Letter_from_Mandelson_to_Thailand.pdf.
238. Mankad, M. (April 13, 2010). Supreme Court of India to hear Bayer's plea for patent linkage.
239. Mara, K. (May 21, 2010). World Health Assembly Creates New Initiative for R&D Financing. Intellectual Property Watch.
240. Mara, K. and New, W. (May 18, 2010). Developing Countries Blast WHO Report on IP, Demand "Credible" Approach. Intellectual Property Watch.
241. March, J. G. and Olson, J. P. (1989). Rediscovering Institutions: The Organisational Basis of Politics. New York: The Free Press.
242. March, J. G. and Olsen, J. P. (1998). The Institutional Dynamics of International Political Orders. International Organization, 52(4), 943-969.
243. Marks, S. P. (2009). Access to Essential Medicines as a Component of the Right to Health. In Clapham, A., Robinson, M., Mahon, C. and Scott Jerbi (ed.), Realizing the Right to Health (Swiss Human Rights Book Vol. 3, ed., pp. 80-99). Zurich: rüffer&rub.
244. Marschik, A. (1998). Too Much Order? The Impact of Special Secondary Norms on the Unity and Efficacy of the International Legal System. European Journal of International Law, 9(1), http://www.ejil.org/pdfs/9/1/1478.pdf.
245. Martens, K. (2005). NGO's and the United Nations: Institutionalization, Professionalization and Adaptation. Basingstoke: Palgrave.
246. Martin, J. and Trenado, E. (August 22, 2007). Letter to Peter Mandelson. Retrieved from http://www.actupparis.org/IMG/pdf/Letter_from_Aides_Actup-Paris_to_Mandelson.pdf.
247. Martino, M. (April 9, 2010). Sanofi Opens R&D Center in China. Fierce Biotech. Retrieved from http://www.fiercebiotech.com/story/sanofi-opens-r-d-center-china/2010-04-09.
248. Mathers, C. D. and Loncar, D. (2006). Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med, 3(11), e442. Retrieved from http://dx.doi.org/10.1371%2Fjournal.pmed.0030442.
249. Mau, S. (2010). Social Transnationalism. Lifeworlds Beyond the Nation State (English ed.) Routledgen.
250. May, C. (2008). The World Intellectual Property Organisation and the Development Agenda. Global Society, 22(1), 97-113. Retrieved from http://www.informaworld.com/10.1080/13600820701740753.
251. Mayne, R. (2002). US Bullying on Drug Patents: One Year After Doha (Oxfam Briefing Paper No. 33). Washington, DC: Oxfam. http://www.oxfam.org.nz/imgs/pdf/drugs_bullying%20mtf.pdf.
252. Mayntz, R. (2005). Governance Theory Als Fortentwickelte Steuerungstheorie? In G. F. Schuppert (ed.), Governance-Forschung. Vergewisserung Über Stand Und Entwicklungslinien. (pp. 11-20). Baden-Baden: Nomos.
253. McDorman, T. L. (1992). US-Thailand Trade Disputes: Applying Section 301 to Cigarettes and Intellectual Property. Michigan Journal of International Law, 14, 90-119.
254. Médecins Sans Frontières (MSF) (March 23, 2005). MSF Statement on the New Indian Patent Bill. Retrieved from http://www.doctorswithoutborders.org/press/release.cfm?id=1494&cat=press-release.
255. Médecins Sans Frontières (MSF) (2005). Untangling the Web of Antiretroviral Price Reductions (8th ed.). Geneva: Médecins Sans Frontières (MSF). http://www.msfaccess.org/fileadmin/user_upload/diseases/hiv-aids/Untangling_the_Web/untanglingtheweb%208.pdf.
256. Médecins Sans Frontières (MSF) (June 22, 2011). India Says No to Policy that Would Block Access to Affordable Medicines. Press Release, http://www.msfaccess.org/media-room/press-releases/press-release-detail/?tx_ttnews[tt_news]=1700&cHash=2f6721d292.
257. Médecins Sans Frontières (MSF) (2011). Untangling the Web of Antiretroviral Price Reductions (Online ed.). Retrieved from http://utw.msfaccess.org/.
258. Meier, B. M. and Labbok, M. (2010). From the Bottle to the Grave: Realizing a Human Right to Breastfeeding through Global Health Policy. Case Western Reserve Law Review, 60(4), 1073-1142. Retrieved from https://docs.google. com/viewer?a=v&pid=explorer&chrome=true&srcid=0Bxj5zdnvGv05NDB mZjM2YjQtODAxOC00OWFiLWJiNjQtNDYxODY4ZjIxNGU2&hl=en_US&pli=1.
259. Menou, V., Hornstein, A. and Lipton-McCombie, E. (2008). Access to Medicine Index: Ranking Access to Medicine Practices. Innovest Healthcare Team. Retrieved from http://www.atmindex.org/index/2008.
260. Merletti, F., Galassi, C. and Spadea, T. (2011). The Socioeconomic Determinants of Cancer. Environmental Health, 10(Suppl 1), S7. doi:10.1186/1476-069X-10-S1-S7. Retrieved from http://www.ehjournal.net/content/10/S1/S7.
261. Ministry of Public Health (Thailand) and National Health Security Office (Thailand). (2007). Facts and Evidences on the 10 Burning Issues Related to the Government use of Patents on Three Patented Essential Drugs in Thailand: Document to Support Strengthening of Social Wisdom on the Issue of Drug Patent. Bangkok: Retrieved from http://www.cptech.org/ip/health/c/thailand/thai-cl-white-paper.pdf.
262. Modelski, G. (2008). Globalization as Evolutionary Process. In Modelski, G., Devezas, T. and Thompson W. R. (eds), Globalization as Evolutionary Process. Modeling Global Change (pp. 11-29). London: Routledge.
263. Moon, S. (2008). Research Report on PDPs for Oxfam International. Unpublished manuscript.
264. Moon, S. (2009). Medicines as Global Public Goods: The Governance of Technological Innovation in the New Era of Global Health. Global Health Governance, 2(2). Retrieved from http://www.ghgj.org/moon2.2medecines publicgood.htm.
265. Moon, S. (2010). Embedding Neoliberalism: Global Health and the Evolution of the Global Intellectual Property Regime (1994-2009). (PhD, Harvard University).
266. Moon, S., Szlezák, N. A., Michaud, C., et al. (2010). The Global Health System: Lessons for a Stronger Institutional Framework. PLoS Medicine, 7(1). Retrieved from http://www.plosmedicine.org/article/info%3Adoi%2F 10.1371%2Fjournal.pmed.1000193.
267. Moran, M. (2005). A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs we Need. PLoS Medicine, 2(9), e302. Retrieved from http://dx.doi.org/10.1371%2Fjournal.pmed.0020302.
268. Moran, M., Guzman, J., Henderson, K., et al. (2009). Neglected Disease Research and Development: New Times, New Trends. Sydney, Australia: The George Institute for International Health.
269. Morin, J. (2008). Dancing with Brazil, South Africa, India and China. Idées Pour Le Débat, 2008(02). Retrieved from http://www.iddri.org/Publications/Collections/Idees-pour-le-debat/Id_0802_JF-Morin_Dancing-EN.pdf.
270. Morin, J. (2009). Multilateralising TRIPs-Plus Agreements: Is the US Strategy a Failure? The Journal of World Intellectual Property, 12(3), 175-197. doi:10.1111/j.1747-1796.2009.00364.x. Retrieved from http://www.allacademic.com/meta/p313466_index.html.
271. Murray, C., Anderson, B., Burstein, R., et al. (2011). Development Assistance for Health: Trends and Prospects. The Lancet, 378, 8-11.
272. Nankivell, T. (2002). Living, Labour and Environmental Standards and the WTO (Staff Working Paper). Melbourne: Productivity Commission.
273. Nation, Thailand. (October 18, 2005). Ministry Seeks Right to make Tamiflu. The Nation (Thailand).
274. New, W. (February 10, 2011). Pharma Backs Calls for Extension of TRIPS Deadline for Least-Developed Countries. IP Watch. Retrieved from http://www.ip-watch.org/weblog/2011/02/10/pharma-backs-calls-for-extension-of-trips-deadline-for-least-developed-countries/.
275. Novartis. (2007). History of Glivec in India. Retrieved from http://www.novartis. com/downloads/about-novartis/glivec-history-india.pdf.
276. Novartis. (2009). Novartis Announces USD 1 Billion Investment to Build Largest Pharmaceutical R&D Institute in China. COMTEX. Retrieved from http://www.fiercebiotech.com/press-releases/novartis-announces-usd-1-billion-investment-build-largest-pharmaceutical-r-d-institut.
277. Novartis. (2010). Pharmaceutical Development. Retrieved from http://www.novartis.com/research/pharmaceutical.shtml.
278. Nunn, A. (2009). The Politics and History of AIDS Treatment in Brazil. New York: Springer Science+Business Media.
279. O'Brien, R., Goetz, A., Scholte, J. A. and Williams, M. (2000). Contesting Global Governance: Multilateral Economic Institutions and Global Social Movements. Cambridge: Cambridge University Press.
280. Oakeshott, V. (2009). The Treatment Timebomb: Report of the Inquiry of the all Party Parliamentary Group on AIDS into Long-Term Access to HIV Medicines in the Developing World. All Party Parliamentary Group on AIDS. Retrieved from http://www.aidsportal.org/repos/APPGTimebomb091.pdf.
281. Oberthür, S. and Gehring, T. (eds) (2006). Institutional Interaction in Global Environmental Governance. Synergy and Conflict among International and EU Policies. Cambridge, MA: MIT Press.
282. Office of the High Commissioner for Human Rights (OHCHR). (2010). EU-India Draft Free Trade Agreement: Generic Medications Under Threat, Says UN Health Expert. Retrieved from http://www.ohchr.org/EN/NewsEvents/Pages/DisplayNews.aspx?NewsID=10592&LangID=E.
283. Office of the United Nations High Commissioner for Human Rights. Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health. Retrieved from http://www2.ohchr. org/english/issues/health/right/.
284. Office of the United Nations High Commissioner for Human Rights (2011, 16 June). News Release: New Guiding Principles on Business and Human Rights Endorsed by the UN Human Rights Council. http://www.business-humanrights.org/media/documents/ruggie/ruggie-guiding-principles-endorsed -16-jun-2011.pdf.
285. Office of the United States Global AIDS Coordinator (2008). The Power of Partnerships: The U.S. President's Emergency Plan for AIDS Relief. 2008 Annual Report to Congress (Fourth annual report). Retrieved from http://www.pepfar.gov/press/fourth_annual_report/.
286. Office of the United States Trade Representative (USTR) (2007). 2007 Special 301 Report. Washington, DC: USTR. Retrieved from http://www.ustr.gov/about-us/press-office/reports-and-publications/archives/2007/2007-special-301-report.
287. Office of the United States Trade Representative (USTR). (2010). 2010 Special 301 Report. Washington, DC: USTR. Retrieved from http://www.ustr.gov/about-us/press-office/reports-and-publications/2010-3.
288. Okediji, R. L. (2004). Back to Bilateralism? Pendulum Swings in International Intellectual Property Protection. University of Ottawa Law & Technology Journal, 1, 125-146. Retrieved from http://ssrn.com/abstract=764725.
289. Open Source Drug Discovery. (2012). Retrieved from http://www.osdd.net/.
290. Our Legal Correspondent (January 20, 2005). MNCs Told to Supply 'Patented' Anti-Cancer Drug. The Hindu Businessline. Retrieved from http://www.blonnet.com/2005/01/21/stories/2005012101590400.htm.
291. Outterson, K. and Smith, R. (2006). Counterfeit Drugs: The Good, the Bad and the Ugly. Albany Law Journal of Science & Technology, 16, 525.
292. Oxfam International. (2007). All Costs, no Benefits: How TRIPS-Plus Intellectual Property Rules in the US-Jordan FTA Affect Access to Medicines (Oxfam Briefing Paper No. 102). Oxford: Oxfam International.
293. Parliament (Kenya). The Anti-Counterfeit Bill, 2008, Paragraph 2 (2008).
294. Pécoul, B., Chirac, P., Trouiller, P. and Pinel, J. (1999). Access to Essential Drugs in Poor Countries: A Lost Battle? Journal of the American Medical Association, 281(4), 361-367. Retrieved from http://jama.ama-assn.org/cgi/content/abstract/281/4/361.
295. Penrose, E. T. (1951). The Economics of the International Patent System. Westport, Connecticut: Greenwood Press, Publishers.
296. Perez-Casas, C., Mace, C., Berman, D. and Double, J. (2001). Untangling the Web of Antiretroviral Price Reductions (1st ed.). Geneva: Medecins Sans Frontieres/Campaign for Access to Essential Medicines. http://www.msfaccess.org/fileadmin/user_upload/diseases/hiv-aids/Untangling_the_Web/UTW%20 1%20Sep%202001.pdf.
297. Piot, P. (December 26, 2006). Letter to Mongkol Na Songkhla.
298. Pogge, T. (2009). The Health Impact Fund: Boosting Pharmaceutical Innovation without Obstructing Free Access. Cambridge Quarterly of Healthcare Ethics, 18(1), 78-86. doi:10.1017/S0963180108090129.
299. Porter, M. (1990). The Competitive Advantage of Nations. New York: The Free Press.
300. Porter, M. and Kramer, M. (2006). The Link between Competitive Advantage and Corporate Social Responsibility. Harvard Business Review, 84(12), 78-92.
301. Press Information Bureau, Ministry of Commerce and Industry, Government of India (March 23, 2005). Important Changes Incorporated in the Patents (Amendment) Bill, 2005 as Compared to the Patents (Amendment) Bill, 2003. Retrieved from http://pib.nic.in/release/release.asp?relid=8096.
302. Price, R. M. (1998). Reversing the Gunsights: Transnational Civil Society Targets Landmines. International Organization, 52(3), 613-644.
303. Public Citizen. (2001). Rx R&D Myths: The Case Against the Drug Industry's R&D "Scare Card". Washington, DC: Public Citizen. Retrieved from http://www.citizen.org/documents/ACFDC.PDF.
304. Public Citizen. (2006). Trans-Pacific FTA. http://www.citizen.org/more-about-trans-pacific-fta.
305. Ravishankar, N., Gubbins, P., Cooley, R. J., et al. (2009). Financing of Global Health: Tracking Development Assistance for Health from 1990 to 2007. The Lancet, 373(9681), 2113-2124. doi:10.1016/S0140-6736(09)60881-3.
306. Reis, R., Vieira, M. F. and Chaves, G. C. (2009). Brazil: Access to Medicines and Intellectual Property in Brazil: A Civil Society Experience. In R. Reis, V. Terto Jr. and M. C. Pimenta (eds), Intellectual Property Rights and Access to ARV Medicines: Civil Society Resistance in the Global South (pp. 12-54). Rio de Janeiro: Brazilian Interdisciplinary AIDS Association (ABIA).
307. Revenga, A., Over, M., Masaki, E., et al. (2006). The Economics of Effective AIDS Treatment: Evaluating Policy Options for Thailand. Washington, DC: The World Bank.
308. Reynolds, J. (July 24, 2007). China's Drive to Promote Invention. BBC News. Retrieved from http://news.bbc.co.uk/2/hi/asia-pacific/6912056.stm.
309. Ridley, D. B., Grabowski, H. G. and Moe, J. L. (2006). Developing Drugs for Developing Countries. Health Affairs, 25(2), 313-324. doi:10.1377/hlthaff.25.2.313.
310. RiskMetrics Group - ESG Analytics. (2010a). Access to Medicine Index: Methodology and Stakeholder Review. Amsterdam: Access to Medicine Foundation. Retrieved from http://www.accesstomedicineindex.org/sites/www.accesstomedicineindex.org/files/general/100621_ATMMethodologyReport_with_correct_back_cover.pdf.
311. RiskMetrics Group - ESG Analytics. (2010b). Access to Medicines Index 2010. Haarlem, The Netherlands: Access to Medicine Foundation. Retrieved from http://www.accesstomedicineindexreport.com/.
312. Rittberger, V. and Zangl, B. (2006). International Organization - Polity, Politics and Policies. Basingstoke: Palgrave Macmillan.
313. Roche Group, T. (July 1, 2009). Roche Launches Novel Program to Ease Tamiflu Access to Developing Countries, Basel, Roche. Retrieved from http://www.roche.com/media/media_releases/med-cor-2009-07-01.htm.
314. Ronit, K. and Schneider, V. (1999). Global Governance through Private Organizations. Governance: An International Journal of Policy and Administration, 12(3), 243-266.
315. Ronit, K. and Schneider, V. (2000). Private Organisations in Global Politics. London: Routledge/ECPR Studies in European Political Science.
316. Rosenau, J. N. (1995). Governance in the Twenty-First Century. Global Governance, 1(1), 13-43.
317. Rosenau, J. N. (1997). Along the Domestic-Foreign Frontier: Exploring Governance in a Turbulent World. Cambridge: Cambridge University Press.
318. Rosendal, G. K. (2006). The Convention on Biological Diversity: Tensions with the WTO TRIPS Agreement over Access to Genetic Resources and the Sharing of Benefits. In S. Oberthür and T. Gehring (eds), Institutional Interaction in Global Environmental Governance - Synergy and Conflict among International and EU Policies. (pp. 79-103). Cambridge, MA: MIT Press.
319. Ruggie, J. G. (1982). International Regimes, Transactions, and Change: Embedded Liberalism in the Postwar Economic Order. International Organization, 36(2), 379-415.
320. Ruggie, J. G. (1992). Multilateralism: The Anatomy of an Institution. International Organization, 46(3), 561-598. Retrieved from http://www.jstor.org/stable/2706989.
321. Ruggie, J. G. (2004). Reconstituting the Global Public Domain - Issues, Actors, and Practices. European Journal of International Relations, 10(4), 499-531.
322. Ruggie, J. G. (2008). Protect, Respect and Remedy: A Framework for Business and Human Rights. (Report of the Special Representative of the Secretary-General on the issue of human rights and transnational corporations and other business enterprises, John Ruggie No. A/HRC/8/5). Geneva: United Nations Human Rights Council.
323. Rust, S. M. (1992). US-Thai Relations during the 1980s: The Issue of Intellectual Property Rights. US Air Force Academy Journal of Legal Studies, 3, 161.
324. Sakboon, M. (November 13, 1999). Bid to Help Poor Fight AIDS Virus - Drug Agency Seeks to Cut Costs. The Nation (Thailand). Retrieved from http://lists.essential.org/pharm-policy/msg00306.html.
325. Sanofi-Aventis. (2008). Sanofi-Aventis Expands its R&D Presence in China. Beijing: Retrieved from http://www.fiercebiotech.com/press-releases/sanofiaventis-expands-its-r-d-presence-china.
326. Schattschneider, E. E. (1960). The Semisovereign People. A Realist's View of Democracy in America. Chicago: Holt, Rinehart and Winston.
327. Schneider, V. and Ronit, K. (1999). Global Economic Governance by Private Actors: The International Chamber of Commerce. In J. Greenwood and H. Jacek (ed.), Organised Business and the New Global Order (pp. 223-240). London: Palgrave Macmillan.
328. Scholte, J. A. (2011). Building Global Democracy? Civil Society and Accountable Global Governance. Cambridge: Cambridge University Press.
329. Schwab, S. (2007). Letter to Thomas Allen. Retrieved from http://www.cptech.org/ip/health/c/thailand/letter.pdf.
330. Sell, S. K. (1998). The Power of Ideas. North-South Politics of Intellectual Property and Antitrust. Albany: State University of New York Press.
331. Sell, S. K. (2003). Private Power, Public Law: The Globalization of Intellectual Property Rights. New York: Cambridge University Press.
332. Sell, S. K. (2008). The Global IP Upward Ratchet, Anti-Counterfeiting and Piracy Enforcement Efforts: The State of Play (IQ Sensato Occasional Paper #1). Geneva: IQ Sensato. Retrieved from http://www.iqsensato.org/wp-content/uploads/Sell_IP_Enforcement_State_of_Play-OPs_1_June_2008.pdf.
333. Sell, S. K. and Prakash, A. (2004). Using Ideas Strategically: The Contest between Business and NGO Networks in Intellectual Property Rights. International Studies Quarterly, 48(1), 143-175. doi:10.1111/j.0020-8833.2004.00295.x.
334. Severino, J. and Ray, O. (2010). The End of ODA (II). The Birth of Hypercollective Action (Working Paper 218). Center for Global Development. Retrieved from http://kms1.isn.ethz.ch/serviceengine/Files/ISN/118485/ipublicationdocument_singledocument/c4d033da-776c-4cd6-896d-9b121f4bcdc1/en/wp218.pdf.
335. Sexton, S. (2001). Trading Health Care Away? GATS, Public Services and Privatization (The Corner House Briefing 23). Dorset: The Corner House. Retrieved from www.thecornerhouse.org.uk/pdf/briefing/23gats.pdf.
336. Shaffer, E. R. and Brenner, J. E. (2009). A Trade Agreement's Impact on Access to Generic Drugs. Health Affairs, 28(5), 957-968. doi:10.1377/hlthaff.28.5.w957. Retrieved from http://www.cpath.org/sitebuildercontent/sitebuilderfiles/cpathhaonline8-25-09.pdf.
337. Shearing, C. and Wood, J. (2003). Nodal Governance, Democracy, and the New 'Denizens'. Journal of Law and Society, 30(3), 400-419.
338. Sikkink, K. (1986). Codes of Conduct for Transnational Corporations: The Case of the WHO/UNICEF Code. International Organization, 40(4), 815-840.
339. Sklair, L. (2001). The Transnational Capitalist Class. Oxford: Blackwell.
340. Smith, A. (1937 [1776]). The Wealth of Nations. New York: The Modern Library.
341. Smith, R., Beaglehole, R., Woodward, D. and Drager, N. (eds) (2003). Global Public Goods for Health. Health Economic and Public Health Perspectives. Oxford: Oxford.
342. Smith, R. A. and Siplon, P. D. (2006). Drugs into Bodies: Global AIDS Treatment Activism. Westport, CT: Praeger.
343. Songkhla, M. N. (2007). Letter to Peter Mandelson. Retrieved from http://www.actupparis.org/IMG/pdf/Answer_Thai.pdf.
344. Stahl, T., Wismar, M., Ollila, E., et al. (2006). Health in all Policies. Prospects and Potentials. Helsinki: Ministry of Social Affairs, Finland. Retrieved from http://ec.europa.eu/health/ph_information/documents/health_in_all_policies.pdf.
345. Steiner, H. J. and Alston, P. (2000). International Human Rights in Context: Law, Politics, Morals (2nd ed.). Oxford: Oxford University Press.
346. Stokke, O. S. (2001). The Interplay of International Regimes. Putting Effectiveness Theory to Work. (FNI Report 14/2001). Lysaker: Fridtjof Nansen Institute.
347. Strandberg, C. (2008). The Role of the Board of Directors in Corporate Social Responsibility. The Conference Board of Canada. Retrieved from http://www.corostrandberg.com/pdfs/08-169The_Role_of_the_Board_of_Directors_in_%20CSR_Report_WEB28.pdf.
348. Strom, S. and Fleischer-Black, M. (June 5, 2003). Company's Vow to Donate Cancer Drug Falls Short. The New York Times. Retrieved from http://www.nytimes.com/2003/06/05/business/05DRUG.html?scp=1&sq=novartis%20 strom%20fleischer%20bac&st=cse.
349. Stuckler, D., Hawkes, C. and Yach, D. (2009). Governance of Chronic Diseases. In K. Buse, W. Hein and N. Drager (eds), Making Sense of Global Health Governance: A Policy Perspective (pp. 268-293). Basingstoke: Palgrave Macmillan.
350. Sturchio, J. L. (February 29, 2008). Response from Merck & Co., Inc. (to Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines).
351. Sukkar, E. (April 28, 2010). Kenya's Anticounterfeit Law Halted by Court Over Generic Question. Scrip World News.
352. Sulzbach, S., De, S. and Wang, W. (2011). The Private Sector Role in HIV/AIDS in the Context of an Expanded Global Response: Expenditure Trends in Five Sub-Saharan African Countries. Health Policy and Planning, 26, 172-184.
353. Swenson, J. (2000). On Jean-Jacques Rousseau. Palo Alto: Stanford University Press.
354. Sykes, R. (2002). Commentary: The Reality of Treating HIV and AIDS in Poor Countries. British Medical Journal, 324(7331), 214-218. doi:10.1136/bmj. 324.7331.214.
355. 't Hoen, E. (2007). Intellectual Property, Bilateral Agreements, and Sustainable Development: A Strategy Note (Intellectual Property, Bilateral Agreements, and Sustainable Development Series: 2). Center for International Economic Law (CIEL). Retrieved from http://www.ciel.org/Publications/IP_StrategyNote_Apr07.pdf.
356. 't Hoen, E. (2009). The Global Politics of Pharmaceutical Monopoly Power: Drug Patents, Access, Innovation, and the Application of the WTO Doha Declaration on TRIPS and Public Health. Diemen, The Netherlands: AMB Press.
357. 't Hoen, E., Berger, J., Calmy, A. and Moon, S. (2011). Driving a Decade of Change: HIV/AIDS, Patents, and Access to Medicines. Journal of the International AIDS Society, 14(15). Retrieved from http://www.jiasociety.org/content/14/1/15.
358. Tantivess, S., Kessomboon, N. and Laongbua, C. (2008). Introducing Government use of Patents on Essential Medicines in Thailand, 2006-2007: Policy Analysis with Key Lessons Learned and Recommendations. Nonthaburi, Thailand: International Health Policy Program, Ministry of Health.
359. Tarrow, S. (2005). The New Transnational Activism. New York: Cambridge University Press.
360. Taylor, L. (August 9, 2010). US Senators Seek Incentives for Pharma R&D into Rare Childhood Diseases. Pharma Times. Retrieved from http://www.pharmatimes.com/WorldNews/article.aspx?id=18331&src=EWorldNews.
361. Thakur, R., Cooper, A. and English, J. (eds) (2005). International Commissions and the Power of Ideas. New York: United Nations University Press.
362. Thauer, C. R. (2011). Goodness comes from within. Intra-firm bargaining, asset specificity, and collective good provision. Presentation at the IPSA-ECPR Joint Conference, Sao Paulo, February 16-19, 2011.
363. The Global Fund to Fight AIDS, Tuberculosis and Malaria (2011). The Global Fund Adopts New Strategy to Save 10 Million Lives by 2016: Reductions in Resource Outlook Limit Funding of New Grants. Retrieved from http://www.theglobalfund.org/en/mediacenter/pressreleases/2011-11-23_The_Global_Fund_adopts_new_strategy_to_save_10_million_lives_by_2016/.
364. The Lancet (2010). Drug Development for Neglected Diseases: Pharma's Influence. The Lancet, 375(9708), 2. doi:10.1016/S0140-6736(09)62123-1.
365. The Office of the President-Elect (2009). The Obama-Biden Plan to Combat HIV/AIDS. Retrieved from http://change.gov/pages/the_obama_biden_plan_to_combat_global_hiv_aids.
366. The World Trade Organization (WTO). Whose WTO is it Anyway? Retrieved from http://www.wto.org/english/thewto_e/whatis_e/tif_e/org1_e.htm.
367. Thomas, C. (2004). Trade Policy and the Politics of Access to Drugs. In N. K. Poku and A. Whiteside (eds), Global Health and Governance: HIV/AIDS (pp. 61-74). Basingstoke: Basingstoke: Palgrave.
368. Tonelson, A. (2000). The Race to the Bottom: Why a Worldwide Worker Surplus and Uncontrolled Free Trade are Sinking American Living Standards. Boulder, CO: Westview Press.
369. Travis, J. (2008a). Research Funding. Prizes Eyed to Spur Medical Innovation. Science (New York, NY), 319(5864), 713. doi:10.1126/science.319.5864.713.
370. Travis, J. (2008b). Science and Commerce. Science by the Masses. Science (New York, NY), 319(5871), 1750-1752. doi:10.1126/science.319.5871.1750.
371. Treerutkuarkul, A. (February 2, 2007). WHO Raps Compulsory Licensing Plan: Govt Urged to Seek Talks with Drug Firms. The Bangkok Post. Retrieved from http://lists.essential.org/pipermail/ip-health/2007-February/010493.html.
372. Treerutkuarkul, A. (February 9, 2007a). Drug Firm Will Cut Cost of Kaletra. Bangkok Post.
373. Treerutkuarkul, A. (March 27, 2007b). Drug-Makers Reject Offer of Royalty Fees. Bangkok Post.
374. Treerutkuarkul, A. (March 16, 2007c). Justice Slams Abbott's Drug Decision. Bangkok Post.
375. Treerutkuarkul, A. (March 15, 2007d). US Drug Giant Hits Back, Says no New Drugs. Bangkok Post.
376. Treerutkuarkul, A. (August 3, 2010). HIV/AIDS Drug Licence Extended. The Bangkok Post. Retrieved from http://www.bangkokpost.com/news/health/189154/hiv-aids-drugs-licence-extended.
377. UN Commission on Human Rights. Access to Medication in the Context of Pandemics such as HIV/AIDS, Resolution 2001/33, 71st Meeting (2001). Retrieved from http://www.unhchr.ch/huridocda/huridoca.nsf/%28 Symbol%29/E.CN.4.RES.2001.33.En?Opendocument.
378. UN Committee on ESC Rights (1999). Statement of the UN Committee on Economic, Social and Cultural Rights to the Third Ministerial Conference of the World Trade Organization (Seattle, November 30 to December 3, 1999), E/C.12/1999/9, November 26, 1999 (47th meeting, 21st session). Retrieved from http://www.unhchr.ch/tbs/doc.nsf/%28Symbol%29/68300503f197ef528 025683b004fbbae?Opendocument.
379. UNAIDS (June 7, 2011). Future of AIDS Response Focus of UN General Assembly High Level Meeting, http://www.unaids.org/en/media/unaids/contentassets/documents/pressrelease/2011/06/20110607_PR_HLM_opener_en.pdf.
380. UNCTAD-ICTSD (ed.) (2005). Resource Book on TRIPS and Development: An Authoritative and Practical Guide to the TRIPS Agreement. Cambridge: Cambridge University Press.
381. Union of International Associations (ed.) (2004). Yearbook of International Organizations. Munich: Saur Verlag.
382. UNITAID Secretariat (2009). UNITAID Patent Pool Initiative: Implementation Plan (UNITAID/EB11/2009). Geneva: UNITAID.
383. United Kingdom Commission on Intellectual Property Rights (CIPR) (2002). Integrating Intellectual Property Rights and Development Policy. London: United Kingdom Department for International Development. Retrieved from http://www.iprcommission.org/graphic/documents/final_report.htm.
384. United Nations Conference on Trade and Development (UNCTAD) (2005). World Investment Report 2005: Transnational Corporations and the Internationalization of R&D. Geneva: United Nations.
385. United Nations Development Programme (UNDP) (1999). Human Development Report 1999. Oxford and New York: Oxford University Press.
386. United Nations Development Programme (UNDP) (2000). Human Development Report 2000: Human Rights and Human Development. Oxford and New York: Oxford University Press. Retrieved from http://hdr.undp.org/en/reports/global/hdr2000/.
387. United Nations Development Programme (UNDP) (2001). Human Development Report 2001: Making New Technologies Work for Human Development. Oxford and New York: Oxford University Press.
388. United Nations Environmental Program (UNEP) and International Institute for Sustainable Development (IISD) (2005). Environment and Trade. A Handbook (2nd ed.). Geneva and Winnipeg: UNEP and IISD.
389. United Nations General Assembly. 2005 World Summit Outcome, A/60/L.1 (2005). Retrieved from http://www.who.int/hiv/universalaccess2010/worldsummit.pdf.
390. United Nations General Assembly. 60/262 Political Declaration on HIV/AIDS, A/RES/60/262, 60th Session, 87th plenary meeting (2006). Retrieved from http://data.unaids.org/pub/Report/2006/20060615_HLM_PoliticalDeclaration_ARES60262_en.pdf.
391. United Nations General Assembly. Political Declaration on HIV/AIDS: Intensifying our Efforts to Eliminate HIV/AIDS. A/65/L.77, 65th (2011). Retrieved from http://www.un.org/ga/search/view_doc.asp?symbol=A/65/L.77.
392. United Nations Sub-Commission on Human Rights. Intellectual Property Rights and Human Rights, Resolution 2000/7, 25th Meeting. (2000). Retrieved from http://www.unhchr.ch/Huridocda/Huridoca.nsf/TestFrame/c462b62cf8a07b13 c12569700046704e?Opendocument.
393. United States Office of the Trade Representative (USTR) (2011). Anti- Counterfeiting Trade Agreement. Retrieved from http://www.ustr.gov/acta.
394. US Global AIDS Coordinator (2008). Report to Congress by the US Global AIDS Coordinator on the use of Generic Drugs in the President's Emergency Plan for AIDS Relief. Washington, DC.
395. US Food and Drug Administration (2011). Antiretroviral drugs used in the treatment of HIV infection. Retrieved from http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm.
396. Velasquez, G., Aldis, B., Timmermans, K., et al. (2008). Improving Access to Medicines in Thailand: The use of TRIPS Flexibilities. Report of a WHO Mission (Bangkok, 31 January to 6 February 2008). Bangkok, Thailand: National Health Security Office.
397. Vivas-Eugui, D. (2003). Regional and Bilateral Agreements and a TRIPS-Plus World: The Free Trade Area of the Americas (FTAA). Geneva: QUNO, QIAP. ICTSD. Retrieved from http://homepages.3-c.coop/tansey/pdfs/ftaa-a4.pdf.
398. Vogel, D. and Kagan, R. (eds) (2004).The Dynamics of Regulatory Change: How Globalization Affects National Regulatory Policies. Berkeley: University of California Press.
399. Waisbord, S. (2011). Can NGOs Change the News? International Journal of Communication, 5, 142-165.
400. Walt, G., Spicer, N. and Buse, K. (2009). Mapping the Global Health Architecture. In K. Buse, W. Hein and N. Drager (eds), Making Sense of Global Health Governance: A Policy Perspective (pp. 72-98). Basingstoke: Palgrave Macmillan.
401. Waning, B., Diedrichsen, E. and Moon, S. (2010). A Lifeline to Treatment: The Role of Indian Generic Manufacturers in Supplying Antiretroviral Medicines to Developing Countries. Journal of the International AIDS Society, 13, 35. doi:10.1186/1758-2652-13-35. Retrieved from http://www.jiasociety.org/content/13/1/35.
402. Watal, J. (2001). Intellectual Property Rights in the WTO and Developing Countries. The Hague: Kluwer Law International.
403. Weber, M. (1947). The Theory of Social and Economic Organization (A. Henderson, T. Parsons Trans.). New York: Free Press.
404. Weber, M. (1978). Economy and Society: An Outline of Interpretive Sociology. New York: University of California Press.
405. Wei, M. (2007). Should Prizes Replace Patents? A Critique of the Medical Innovation Prize Act of 2005. Boston University Journal of Science and Technology Law (Working Paper). Retrieved from http://www.cptech.org/ip/health/prizefund/files/wei-prizepaper.pdf.
406. Wellens, K. C. (1995). Diversity in Secondary Rules and the Unity of International Law: Some Reflections on Current Trends. In L. A. Barnhoom and K. C. Wellens (eds), Diversity in Secondary Rules and the Unity of International Law (pp. 3-37). The Hague: Nijhoff.
407. WHO Consultative Expert Working Group on Research and Development (CEWG) (2011). Report of the Second Meeting of the Consultative Expert Working Group on Research and Development: Financing and Coordination. Geneva: Retrieved from http://www.who.int/phi/news/cewg_rd_2nd_meeting_report.pdf.
408. WHO Consultative Expert Working Group on Research and Development (CEWG): Financing and Coordination (2012). Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination (Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination. Geneva: World Health Organization. Retrieved from http://www.who.int/phi/CEWG_Report_5_April_2012.pdf.
409. Wiener, A. (2008). The Invisible Constitution of Politics. Contested Norms and International Encounters. Cambridge: Cambridge University Press.
410. Wilson, D. (March 6, 2011). Drug Firms Face Billions in Losses in '11 as Patents End. The New York Times, http://www.nytimes.com/2011/03/07/business/07drug. html?scp=1&sq=china%20price%20controls%20pharmaceutical&st=cse.
411. Wilson, D., Cawthorne, P., Ford, N. and Aongsonwang, S. (1999). Global Trade and Access to Medicines: AIDS Treatments in Thailand. The Lancet, 354(9193), 1893-1895. doi:10.1016/S0140-6736(99)06114-0.
412. Wilson, P. (2010). Giving Developing Countries the Best Shot: An Overview of Vaccine Access and R&D. Geneva: Oxfam International and MSF Campaign for Access to Essential Medicines.
413. Wimmer, A. and Glick Schiller, N. (2002). Methodological Nationalism and Beyond: Nation-State Building, Migration and the Social Sciences. Global Networks, 2(4), 301-334. Retrieved from, http://www.sscnet.ucla.edu/soc/faculty/wimmer/B52.pdf.
414. Windfuhr, M. (ed.) (2005). Beyond the Nation State - Human Rights in Times of Globalization (Uppsala: Global Publications Foundation).
415. Wisartsakul, W. (2004). Civil Society Movement to Revoke the Thai Patent on ddI (N. Grant Trans.). Bangkok: Medecins Sans Frontieres-Belgium.
416. Wiseman, G. (1999). Polylateralism and New Modes of Global Dialogue (Discussion Paper No. 59). Leicester: Leicester Studies Program.
417. Wogart, J. P., Calcagnotto, G., Hein, W. and Soest, C. V. (2009). AIDS and Access to Medicines: Brazil, South Africa and Global Health Governance. In K. Buse, W. Hein and N. Drager (eds), Making Sense of Global Health Governance: A Policy Perspective (pp. 137-163). Basingstoke: Palgrave Macmillan.
418. World Health Assembly. Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. Resolution 61.21, Sixty-first Assembly. (2008). Retrieved from http://www.who.int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf.
419. World Health Organization (WHO) (2004). World Medicines Situation (WHO/EDM/PAR/2004.5). Geneva: WHO.
420. World Health Organization (WHO) (2006). Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. 2006 Revision. Geneva: WHO.
421. World Health Organization (WHO) (2009). Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva: World Health Organization.
422. World Health Organization (WHO) (2011). Essential Medicines. Retrieved from http://www.who.int/topics/essential_medicines/en/.
423. World Health Organization (WHO), UNICEF, UNAIDS (2010). Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2010. Geneva: WHO. Retrieved from http://www.who.int/hiv/pub/2010progressreport/en/index.html.
424. World Health Organization (WHO), UNICEF, UNAIDS (2011). Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access. Progress Report 2011. Retrieved from http://www.who.int/hiv/pub/progress_report2011/en/index.html
425. World Health Organization (WHO) and World Trade Organization (WTO) (2002). WTO Agreements and Public Health. A Joint Study by the WHO and the WTO Secretariat. Geneva: World Health Organization and World Trade Organization. Retrieved from http://www.who.int/trade/resource/wtoagreements/en/index.html.
426. World in Brief. (2006, December 1). The Washington Post.
427. World Intellectual Property Organization (WIPO) (2009). Treaties Statistics: Paris Convention of March 20, 1883. Retrieved from http://www.wipo.int/treaties/en/statistics/StatsResults.jsp?treaty_id=2.
428. World Intellectual Property Organization (WIPO) (2010). A Medium Term Strategic Plan for WIPO, 2010-2015: First Draft Presented to Member States by the Director General on May 27, 2010. Geneva: WIPO. Retrieved from http://www.wipo.int/export/sites/www/about-wipo/en/pdf/mtsp.pdf.
429. World Intellectual Property Organization (WIPO) (2012). Statistics on the PCT System; PCT Filings by Country of Origin. Retrieved from http://www.wipo.int/ipstats/en/statistics/pct/.
430. World Trade Organization (WTO) (2010a). Dispute Settlement: Dispute DS408: European Union and a Member State - Seizure of Generic Drugs in Transit. Retrieved from http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds408_e.htm.
431. World Trade Organization (WTO) (2010b). Dispute Settlement: Dispute DS409: European Union and a Member State - Seizure of Generic Drugs in Transit. Retrieved from http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds409_e.htm.
432. World Trade Organization (WTO) (2010c). Dispute Settlement: DS224: United States - US Patents Code. Retrieved from http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds224_e.htm.
433. World Trade Organization (WTO) (2010d). Members Ask: Is the "Par.6" System on Intellectual Property and Health Working? 2010 News Items.
434. World Trade Organization (WTO) (2011). TRIPS: 'Non-Violation' Complaints (Article 64.2). Retrieved from http://www.wto.org/english/tratop_e/trips_e/nonviolation_background_e.htm.
435. Wright, T. (December 12, 2005). Roche Picks Chinese Partner for Tamiflu. The New York Times.
436. Young, O. R. (1996). Institutional Linkages in International Society. Global Governance, 2, 1-23.
437. Ziemba, E. (2005). Public-Private Partnerships for Product Development: Financial, Scientific, and Managerial Issues as Challenges to Future Success (Research report for the WHO Commission on Intellectual Property Rights, Innovation, and Public Health).